The role of gonadotropins in follicular development and their use in ovulation induction protocols for assisted reproduction

European Journal of Contraception and Reproductive Health Care

Volumn 5, Issue 2, 2000, Pages 157-167

  Zafeiriou, S ^a   Loutradis, D ^a   Michalas, S ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Follicular growth and maturation; GnRH analogs; Growth factors; Ovulation induction; Recombinant FSH; Steroidogenesis; Stimulation protocols; Urinary gonadotropins

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE;

EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HUMAN; HYPOPHYSECTOMY; LUTEINIZATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY; PRIORITY JOURNAL; REPRODUCTION; REVIEW; STEROIDOGENESIS;

EID: 0033926142     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/13625180008500389     Document Type: Review

References (52)

1. 1. Richards JS. Maturation of ovarian follicles and interactions of pituitary and ovarian hormones on follicle wall differentiation. Physiol Rev 1980;60:51
2. 2. McNatty KP, Hunter WM, McNeilly AS, et al. Changes in the concentration of pituitary and steroid hormones in the follicular fluid of human Graafian follicles throughout the menstrual cycle. J Endocrinol 1975;64:555
3. 3. McNatty KP, Sawers RS. Relationship between the endocrine environment within the Graafian follicle and the subsequent rate of progesterone secretion by human granulosa cells in culture. J Endocrinol 1975;66: 391
4. 4. Horie K, Takakura K, Fujiwara H, et al. Immuno-histochemical localization of androgen receptor in the human ovary throughout the menstrual cycle in relation to estrogen and progesterone receptor expression. Hum Reprod 1992;7:184-90
5. 5. Chappel S, Howles C. Preevaluation of the roles of luteinizing hormone and follicle stimulating hormone in the ovulatory process. Hum Reprod 1991;6:1206-12
6. 6. Rabinovici J, Blankstein J, Goldman B, et al. In vitro fertilization and primary embryonic cleavage are possible in 17-hydroxylase deficiency despite extremely low intrafollicular 17-estradiol. J Clin Endocrinol Metab 1989; 68:693-7
7. 7. Levine JE, Norman RL, Glessman PM, et al. In vivo gonadotropin-releasing hormone measurements in ovariectomized, estrogen-treated Rhesus monkeys. Endocrinology 1985;117:711-21
8. 8. Edwards R, Brody S. Principles and Practice of Assisted Human Reproduction. Philadelphia: Saunders, 1995:182
9. 9. Adashi EY, Resnick CE, D'Ercole AJ, et al. Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocr Rev 1985;6:400-20
10. 10. Doerr P. Relationship between saturation of LH receptors and steroidogenic response in isolated rat granulosa cells. Horm Metab Res 1979;11:181-2
11. 11. Hodgen G, Naftolin F, Cherney AH, eds. The Control of Follicular Development, Ovulation and Luteal Function. New York: Raven Press, 1987:177
12. 12. Couzinet B, Lestrat N, Brailly S, et al. Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency. J Clin Endocrinol Metab 1988;66:552-6
13. 13. Baird DT. Ovulation fertility and infertility: lessons from basic research. In Edwards RG, ed. Establishing a Successful Human Pregnancy. New York: Raven Press, 1990:5
14. 14. Lunenfeld B, Insler V, Rabau E. Induction de l'ovulation par les gonadotrophines. In Moricard R, Ferin J, eds. L'Ovulation. Paris: Masson, 1969:27
15. 15. Oelsner G, Bider D, Maschiach S. Pregnancy rate and first-trimester outcome. In Barnea ER, Hustin J, Jauniaux E, eds. The First Twelve Weeks of Gestation. Berlin: Springer-Verlag, 1992:217-33
16. 16. Loutradis D, Kallianidis K, Siskos K, et al. Combined GnRH agonist and HMG therapy in patients with stimulation failure. Int J Gynecol Obstet 1991;36:317-21
17. 17. Hillier SG, Afnan AM, Margara RA. Superovulation strategy before in vitro fertilization. Clin Obstet Gynaecol 1985;12:687-723
18. 18. Zimmermann R. Gonadotropin therapy of female infertility. Analysis of results in 416 cases. Gynecol Obstet Invest 1982;14:1-4
19. 19. Loutradis D, Kallianidis K, Sakellaropoulos G. Outcome of ovarian response after suppression with a gonadotropin releasing hormone agonist in different chronological periods prior to gonadotropin stimulation for in vitro fertilization. Gynecol Obstet Invest 1991; 32:68-71
20. 20. Tanbo T, Dale PO, Kjekshus E, et al. Stimulation with human menopausal gonadotropin versus follicle stimulating hormone after pituitary suppression in polycystic ovarian syndrome. Fertil Steril 1990;53:798-803
21. 21. Acharya U, Small J, Randall S, et al. Prospective study of short and long regimens of gonadotropin-releasing hormone agonist in in vitro fertilization program. Fertil Steril 1992;57:815-18
22. 22. Belaisch-Allart J, Testart J, Frydman R, et al. Utilization of GnRH agonists for poor responders in an IVF programme. Hum Reprod 1989;4:33-4
23. 23. Klingmuller D, Diedrich K, Sommer L. Effects of the GnRH antagonist cetrorelix in normal women. Gynecol Endocrinol 1993;7:2-8
24. 24. Olivennes F, Fanchin R, Bouchard P, et al. Scheduled administration of a gonadotrophin-releasing hormone antagonist (cetrorelix) on day 8 of in vitro fertilization cycles: a pilot study. Hum Reprod 1995;10:1382-6
25. 25. Shaw RW, Ndukwe G, Imoedemhe DA, et al. Twin pregnancy after pituitary desensitization with LHRH agonist and pure FSH. Lancet 1985;2:506-7
26. 26. Edelstein MC, Drzyski RG, Jones GS, et al. Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression. Fertil Steril 1990;53:103-6
27. 27. Duijkcrs IJ, Vemer HM, Hollanders JM, et al. Different follicle stimulating/luteinizing hormone ratios for ovarian stimulation. Hum Reprod 1993;8:1387-91
28. 28. Loutradis D, Vardaki E, Zafeiriou S, et al. Small doses of LH are needed early in ovarian stimulation for better quality oocytes in IVF-ET. Hum Reprod 1998;13(Abstr book 1):68
29. 29. Diedrich K, Van der Ven H, Al-Hasani S, et al. Ovarian stimulation for in-vitro fertilization. Hum Reprod 1988;3: 39-44
30. 30. Hoffman DI, Lobo RA, Campeau JD, et al. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone. J Clin Endocrinol Metab 1985;60:922-7
31. 31. Kreiner D, Itskovitz J, Droesch K, et al. Serum follicle-stimulating hormone inhibition is a marker for preovulatory oocytcs in in-vitro fertilization and embryo transfer. Hum Reprod 1989;4:381-3
32. 32. Poland ML, Daniele A, Russell JB, et al. Ovulation induction with human menopausal gonadotropin compared to human urinary follicle-stimulating hormone results in a significant shift in follicular fluid androgen levels without discernible differences in granulosa-luteal cell function. J Clin Endocrinol Metab 1986;63: 1284-91
33. 33. Robertson WR. Gonadotrophin isoform pattern in different pharmaceutical preparations. In Kahn JA, ed. Gonadotrophin Isoforms. Facts and Future. Serono Fertility Series, vol 2. Copenhagen, Denmark: Ciconia Foundation, 1997:53-60
34. 34. Germond M, Dessole S, Senn A, et al. Successful in vitro fertilization and embryo transfer after treatment with recombinant human FSH. Lancet 1992;339:1170-1
35. 35. Out HJ, Mannaerts BM, Driessen SG, et al. A prospective randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum Reprod 1995;10:2534-40
36. 36. Out HJ, Driessen SG, Mannaerts BM, et al. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertil Steril 1997;68:1
37. 37. Daya S, Gunby J. Recombinant versus urinary follicle stimulating hormone for ovulation stimulation in assisted reproduction. Hum Reprod 1999;14:2207-15
38. 38. Thornton SJ. Starting doses in IVF and effects on outcome [Abstract]. Hum Reprod 1996;11:104
39. 39. Devroey P, Tournage H, Van Steirteghem A, et al. The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization. Hum Reprod 1998;13:565-6
40. 40. Out HJ, Reimitz PE, Coelingh Bennink HJT. A prospective, randomized study to assess the tolerance and efficacy of intramuscular and subcutaneous administration of recombinant follicle-stimulating hormone (Puregon). Fertil Steril 1997;67:278-83
41. 41. Hornnes P, Giroud D, Howles C, et al. Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol secretion and pregnancy in World Health Organization group II anovulatory women. Fertil Steril 1993;60:724-6
42. 42. Burat J, Burat HM, Marcolin G, et al. Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective. Fertil Steril 1989;52:553-9
43. 43. Shoham Z, Patel A, Jacobs HS. Polycystic ovary syndrome: safety and effectiveness of a stepwise and low-dose administration of purified FSH. Fertil Steril 1991;55:1051-6
44. 44. Van Santbrink EJP, Donderwinkel PFJ, Van Dessel TJHM, et al. Gonadotropin induction of ovulation using a step-down dose regimen: single center clinical experience in 82 patients. Hum Reprod 1995;10:1048
45. 45. Van Santbrink EJP, Fauser BCJM. Urinary follicle hormone for normogonadotropic clomiphene-resistant infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens. J Clin Endocrinol Metab 1997;82:3597-602
46. 46. Van Dessel HJHM, Donderwinkel PFJ, Coelingh Bennink HJT, et al. First established pregnancy and birth after induction of ovulation with recombinant human follicle-stimulating hormone in polycystic ovary syndrome. Hum Reprod 1994;9:55-6
47. 47. Hugues JN, Cedrin-Durnedin I, Avril C, et al. Sequential step-up and step-down dose regimen: an alternative method for ovulation induction with FSH in polycystic ovary syndrome. Hum Reprod 1996;11:2581-4
48. 48. Coelingh Bennink HJT, Fauser BCJM, Out HJ, et al. Recombinant FSH (Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene-resistant normogonadotropic chronic anovulation: a prospective, multicenter, assessor-blind, randomized clinical trial. Fertil Steril 1998;69:19-25
49. 49. Le Contonnec J-Y, Porchet HC, Beltrami V, et al. Clinical pharmacology of recombinant human luteinizing hormone. Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. Fertil Steril 1998;69:189-94
50. 50. Le Cotonnec J-Y, Porchet HC, Beltrami V, et al. Clinical pharmacology of recombinant human luteinizing hormone. Part II. Bioavailability of recombinant human luteinizing hormone in humans assessed with an immunoassay and bioassay. Fertil Steril 1998;69: 195-200
51. 51. Chandrasekher YA, Hutchison JS, Zelinski-Wooten MB, et al. Initiation of periovulatory events in primate follicles using recombinant and native human luteinizing hormone to mimic the midcycle gonadotropin surge. J Clin Endocrinol Metab 1994;79:298-306
52. 52. Imthurn B, Piazzi A, Loumaye E. Recombinant human luteinizing hormone to mimic mid-cycle LH surge. Lancet 1996;248:332-3